
A 2026 IBS pilot found stable symptoms and bacterial changes with a specific fiber blend. See how its design shapes the low-FODMAP takeaway.

On September 24, 2026, a pilot trial of ur gut was published online in the European Journal of Nutrition; MindBodyGreen’s report on the paper describes stable IBS symptoms and changes in gut bacteria during the intervention. Edith Cowan University researchers tested the resistant-starch-and-psyllium blend in adults already following a low-FODMAP diet.
The established dietary framework was not permanent restriction. Monash University describes the low-FODMAP approach as a guided three-step process that includes food reintroduction and personalization. That framework matters when interpreting any study of a supplement used alongside the diet: the powder is being tested within an existing dietary approach rather than replacing it.
Before this pilot, research had also raised questions about how low-FODMAP diets affect gut bacteria. A 2022 meta-analysis summarized in Trulo Foods’ commercial report covered nine trials involving 403 patients. It found lower Bifidobacteria during low-FODMAP diets but no clear effect on overall microbial diversity.
Those findings describe different aspects of the microbiome, the community of microbes in the gut. A change in a particular bacterial group is not the same measurement as a change in overall diversity. Neither result should automatically be translated into a judgment that a diet is helping or harming someone’s health.
The earlier evidence therefore supplied a research question rather than a simple nutritional rule: could a particular fiber preparation change microbial composition while remaining tolerable for people following this diet? The new trial examined that question in a specific setting. It did not begin with evidence that every bacterial change needs correcting.
This distinction also matters when assessing broader claims about dietary variety and microbial diversity. A dietary pattern and a laboratory measurement need to be considered alongside the outcomes that matter to the person eating the food.
According to reporting on the trial, this was a randomized, double-blind pilot. Participants had diagnosed irritable bowel syndrome and were already following a low-FODMAP diet. The intervention followed a one-week baseline period.
The most important design detail is the comparison powder. It contained psyllium but did not contain the resistant-starch component. Both groups therefore received a powder containing fiber.
This was not a test of the blend against taking no fiber. It examined the addition of resistant starch in the context of psyllium. That narrower comparison is essential when deciding what the findings say about the ingredients.
Both groups gradually increased their assigned powder before using the full study amount. The study therefore examined a structured intervention rather than an immediate switch to the final amount. These details describe the research conditions; they are not a personal supplement plan.
The comparator also prevents a common reading error. A result from a blend does not automatically establish that the same result would occur with either ingredient alone. Here, the useful comparison is between the two preparations the researchers actually tested.
The researchers reported that IBS symptom severity and daily gut symptoms did not worsen during the intervention. In its public summary of the research, Edith Cowan University emphasized that participants maintained stable symptoms while showing changes in gut microbiota and gut-related anxiety.
Symptom stability answers a tolerance question. It describes what happened to participants’ symptoms while they used the study preparation. Symptom relief is a different outcome: stable symptoms should not be rewritten as an improvement in IBS.
The trial also reported that average total fiber intake in the blend group reached 33.1 grams per day by the end of the intervention. That total included fiber from the supplement. It is a description of intake in this group rather than an established intake target for everyone with IBS.
Taken together, these findings connect the dietary intervention with participants’ reported experience. They are more informative than a fiber total alone because the researchers also tracked how participants felt during the intervention.
MindBodyGreen’s account reported a 5.5-fold increase in the bacterial group Ruminococcus E in the blend group. Prevotella also increased. These were findings about microbial composition, meaning the mix of bacteria measured in the gut.
The size of a bacterial change can make a headline sound decisive. Its meaning still depends on the outcome being discussed. An increase in a bacterial group is a biological observation; whether people experience a meaningful health benefit is a separate clinical question.
The study also reported lower gut-specific anxiety in the blend group. This adds another outcome to examine alongside symptoms and bacterial measurements. It should be assessed on its own terms rather than treated as evidence that the bacterial changes caused the anxiety result.
A useful way to read the paper is to keep its outcomes separate:
Keeping these categories distinct makes the research easier to interpret without turning several observations into one broad claim about improved gut health.
The analyzed sample included 26 adults, with 13 assigned to the blend and 13 to the comparison powder. Of those participants, 23 were women. This small and unevenly represented sample provides limited information about how responses might differ across the broader IBS population or among people outside that population.
The intervention lasted three weeks. That duration does not establish whether the bacterial changes persist or whether longer use produces a meaningful clinical benefit. The paper also described some mental-health findings as requiring caution because of the sample size and study duration. The gut-specific anxiety result belongs within that caution rather than being presented as evidence of an anxiety treatment.
The researchers reported no intervention-related changes in measured short-chain fatty acids in stool. They also reported no changes in the inflammatory markers that could be analyzed, sleep measures or overall diet-quality measures. These results keep the interpretation tied to the outcomes that actually changed.
Some blood results could not be analyzed adequately because many measurements were below detection limits. An inadequately measurable result is not the same as a confirmed absence of biological activity. Equally, the findings do not support claims that the blend improved inflammation or short-chain fatty acid production.
This separation between a microbial measurement and an everyday outcome is also useful when reading research that assesses butyrate alongside bowel function. Each measurement answers its own question.
Trulo Foods’ report states that ur gut is commercially available and was co-created by researchers involved in the study. That connection is relevant context for readers assessing claims about the tested preparation. The commercial report should not be mistaken for independent confirmation of the findings.
The results also remain specific to the studied formulation and comparison. They are not evidence that all fiber supplements or all resistant-starch-and-psyllium combinations produce the same effects. Edith Cowan University described the work as preliminary and called for larger studies examining longer-term effects and broader IBS populations.
For daily food decisions, the most useful takeaway is a better question rather than a new supplement rule: what evidence supports a particular fiber choice within the person’s current dietary plan? For someone managing IBS with a low-FODMAP approach, that discussion belongs with a qualified healthcare professional who can consider individual needs and the diet’s reintroduction and personalization stages.
This pilot gives researchers a reason to keep studying the specific blend. It does not establish a new standard of care. The sensible direction remains a guided dietary process in which symptom experience and nutritional choices matter alongside laboratory findings. A striking bacterial change should inform the conversation rather than decide the menu.
Fiber choices sit with the adult managing meals and the healthcare professionals advising them; DigestGenius brings research explanations into that decision. Its free educational articles and detailed resources clarify why a measured bacterial change differs from an established dietary benefit, helping readers assess preliminary microbiome findings alongside the evidence on digestive wellbeing.
DigestGenius publishes research-led guidance on digestion, the gut microbiome, fiber, probiotics, gut-brain signaling, inflammation and everyday digestive wellbeing.



Explore clear, research-led guidance on digestion, the microbiome, food, fiber, probiotics and the gut-brain connection.
read the blog